A phase I clinical trial evaluating intravenous Oncoprex monotherapy, also known as FUS1
nanoparticles, demonstrated antitumor activity in lung cancer patients.
Blinded analysis of pretreatment and post-treatment biopsies of three patients' tumors show that expression of FUS1 was absent from pretreatment samples while a high level of FUS1 was expressed in tumors after treatment.
The FUS1 nanoparticle formulation was developed and tested at M.
Introgen obtained a license to the FUS1 gene from M.
AUSTIN, Texas -- Two powerful tumor suppressor genes, p53 and FUS1, administered intravenously in nanoparticle formulations were capable of significantly shrinking metastatic tumors in models of human lung cancer, according to investigators at The University of Texas M.
Abnormalities of the p53 and FUS1 tumor suppressors are among the most common molecular defects found in human cancers.
Introgen's senior vice president, Medical and Scientific Affairs stated, "These results further support our continued clinical development of p53 and FUS1 tumor suppressor therapies.
Being able to deliver cancer-specific tumor suppressor genes, such as FUS1 and p53, may provide new therapeutic options for cancer patients.
Combining the systemic delivery capabilities of the nanoparticle delivery with the cancer-specific activity of tumor suppressor genes, such as FUS1, may provide a new approach to addressing that challenge.
FUS1 is a tumor suppressor and is the active component of INGN 401.
FUS1 was identified by a consortium of researchers from M.
FUS1 is a tumor suppressor and 96 percent of non-small cell lung cancers lack FUS1 protein activity," said Dr.